The PRWIRE Press Releases https:// 2020-05-27T04:09:10Z Manage Pandemic Risks with The Covid-19 Risk Assessment Module 2020-05-27T04:09:10Z manage-pandemic-risks-with-the-covid-19-risk-assessment-module The purpose of the COVID-19 Reporting Module is to allow people to report either a suspicion of or actual COVID-19 illness. It is designed to facilitate effective communications to HR and provide advice to affected individuals based on government guidelines. How does it work? Risks can be assessed by category eg health, financial, legal, and reputational. Once identified, risks are evaluated through risk rating. Control strategies are then evaluated and corrective actions assigned. Viking Analytics provides a visual guide to your overall Covid-19 Risk Assessment Compare initial and residual risk ratings by category View risk assessments by status, assigned persons, and category. View actions assigned, completed and outstanding risk assessments by status, category and assigned persons. Join a Webinar on June 2nd, watch a short video or request a quote https://myosh.com/modules/covid-19-risk-assessments/ Elite Physiotherapists Introduce Online Telehealth Consultations 2020-05-26T06:43:03Z elite-physiotherapists-introduce-online-telehealth-consultations Rob O’Mahony, Kinima Physio co-director and senior physiotherapist, announced that he and his co-director, Alina Tran are offering safe, secure, and convenient online consultations in response to the COVID-19 pandemic. Individuals can access the service from the comfort of their own home through a privately encrypted online video platform from multiple types of digital devices. Telehealth visits have existed for many years and multiple prestigious studies have demonstrated that a telehealth visit can be just as effective as a face-to-face visit for improving injuries, health, and quality of life. Each individual receives a clear diagnosis and management plan that encompasses self-treatment measures and a tailored exercise program that can be performed at home. The movements will be demonstrated and supervised online during the consultation. Perth physio online provides guidance and support every step of the way for injury recovery. The telehealth visits are eligible for rebates and covered by Australian health funds. Telehealth visits are $70 AUD for the initial 45 minute consultation and $60 AUD for 30 minute follow-up consultations. The telehealth visits are available from 7 a.m.-7 p.m. Monday-Friday, 7 a.m.-1 p.m. on Saturday, and Sundays by appointment only. No one has to suffer in silence with the availability of online telehealth physiotherapy at Kinima Physio. It’s an ideal way for individuals to receive safety screens and post-discharge check-ups, preventative and wellness services, and rehabilitation and post-surgical monitoring. It’s also effective for mobility assessments and safety evaluations to prevent hospital readmissions. One of the most prevalent injuries as people are spending more time at home, even with the loosening of restrictions, are neck and shoulder injuries. Individuals are working at less than optimal work stations, exercising from home using unfamiliar equipment, and completing a range of home maintenance tasks to keep busy. Perth shoulder physio can be addressed and administered through telehealth visits and individuals can be referred if appropriate. Kinima Physio offers individualized management for sports injuries, spinal conditions, injury prevention, and orthopaedic surgical rehabilitation for the entire body. The focus on telehealth physio services online is an innovative way that Kinima Physio is committed to providing a high quality service to the people of Perth and now Australia.  About Kinima Physio At Kinima Physio, we integrate clinical excellence with a unique client experience to create a local health movement that empowers as many people as possible. With 25 years of combined experience in the physiotherapy and health industries, including elite sports and orthopaedics, we offer the latest evidence-based treatment programs to instill clarity and understanding, restore function and confidence, and drive high performance. Connect with us on Instagram and Facebook. Media Contact Kinima Physio Email: hello@kinimaphysio.com.au Website: www.kinimaphysio.com.au Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus 2020-05-20T12:24:16Z strong-effectiveness-of-nanoviricides-drug-candidates-observed-in-an-animal-model-of-infection-by-an-ace2-using-human-coronavirus      May 20, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.NanoViricides is developing an animal model for coronavirus infection using hCoV-NL63 as a surrogate for SARS-CoV-2, the virus that causes COVID-19 disease. HCoV-NL63 is a circulating human coronavirus that causes a disease that is similar to SARS-CoV-2, but much milder. Both viruses utilize the same cell receptor, namely ACE2, to gain entry into the cell. Because it causes a mild disease, hCoV-NL63 can be used in BSL2 environments, and the Company believes it is a useful surrogate for development of therapeutics against SARS-CoV-2 infection.In this lethal direct-lung-infection model, animals in all groups developed lung disease which later led to multi-organ failures, a clinical pathology resembling that of the SARS-CoV-2. Reduction in loss of body weight at day 7 was used as the primary indicator of drug effectiveness. Rats were infected directly into lungs with lethal amounts of hCoV-NL63 virus particles and then different groups were treated separately with five different nanoviricides drug candidates, remdesivir as a positive control, and the vehicle as a negative control. The treatment was intravenous by tail-vein injection once daily for five days, except in the case of remdesivir wherein it was by tail-vein injection twice daily.Animals treated with the five different nanoviricides showed significantly reduced body weight loss. The body weight loss was only 3.9% for the best nanoviricide candidate, ranging to 11.2% for the potentially least effective one, as compared to 20% in the vehicle-treated control group, in female animals (n=5 in each group). Male animals treated with the same nanoviricides also showed significantly reduced body weight loss. The body weight loss in male animals was 8.0% for the best nanoviricide candidate and ranged up to 10.9% for the potentially least effective one, as compared to 25% in the vehicle-treated control group (n=5 in each group). In comparison, remdesivir treatment led to a body weight loss of 15.2% in females and 18.6% in males in this study (see below). Smaller numbers mean less loss in body weight compared to starting body weight in the group, and indicate greater drug effectiveness.The strong effectiveness of nanoviricide drug candidates in this model is consistent with the effectiveness observed in cell culture studies against infection of both hCoV-NL63, which was used in this study, and hCoV-229E, another circulating coronavirus that uses a distinctly different receptor, namely APN.Thus this study corroborates the previous cell-culture effectiveness reported by the Company and provides confidence to the Company that these nanoviricides drug candidates may be expected to result in a clinical candidate to be pursued in human clinical trials.The Company believes the fact that these nanoviricides anti-coronavirus drug candidates are highly effective against two distinctly different coronaviruses that use different cellular receptors is very significant. Specifically, it provides a rational basis to scientists indicating that even if the SARS-CoV-2 coronavirus mutates, the nanoviricides can be expected to continue to remain effective.Importantly, nanoviricides are designed to act by a novel mechanism of action, trapping the virus particle like the "Venus-fly-trap" flower does for insects. Antibodies, in contrast, only label the virus for other components of the immune system to take care of. It is well known that the immune system is not functioning properly at least in severe COVID-19 patients.The Company believes that these nanoviricides drug candidates are potentially superior to favipravir, based on cell culture studies and may be superior to remdesivir based on the results of this study, however, a definite conclusion to that effect cannot be drawn. Oral favipravir and infusion of remdesivir are two anti-viral drugs in clinical trials for the treatment of COVID-19.Prior to filing for human clinical trials, NanoViricides plans on conducting studies to further determine the effectiveness against SARS-CoV-2, perform drug development studies for safety/toxicology, and request a pre-IND Meeting with the US FDA for regulatory guidance.Human coronavirus NL63 (hCoV-NL63) uses the same ACE2 receptor as the SARS-CoV-2 that causes CoVID-19. Both in terms of its clinical pathology, and its receptor usage, it is known to be very similar to SARS-CoV-2, except much milder. Therefore the Company believes hCoV-NL63 is a good surrogate model for therapeutics development against SARS-CoV-2. HCoV-NL63 can be studied in a BSL2 lab whereas SARS-CoV-2 currently requires a BSL3 or BSL4 facility.The striking difference in weight loss between the two sexes in this animal model was remarkable. It has been widely reported that men are more likely to suffer severe infection and fatalities from SARS-CoV-2 than women in the current pandemic. This feature was replicated in our animal model study indicating that biological sex differences are the driver of the differences in the severity of infection by the coronaviruses that utilize the ACE2 receptor.The various receptors used by different coronaviruses appear to fall in the broad family of membrane-associated serine proteases. As a family, they share several structural features. Their substrate specificities are dictated by specific amino acid residues and their positions. However, the coronaviruses do not appear to insert into the specific substrate sites on their receptors as can be broadly deduced from limited, available knowledge of these interactions. NanoViricides believes that this has made it possible for the Company to develop receptor-mimetic virus-binding ligands that have broad-spectrum effectiveness against multiple coronaviruses that use different receptors.HCoV-NL63 is known to cause severe lower respiratory tract infections in young children leading to hospitalization. The symptoms are generally less severe than SARS-CoV-2 but are similar. In most cases, hCoV-NL63 causes relatively mild disease, often associated with croup, bronchiolitis, and lower respiratory tract disease in children, and is considered to cause some of the common colds in adults. Thus, the clinical manifestation of hCoV-NL63 infection in pediatric patients is similar to that of SARS-CoV-2, although much less severe. SARS-CoV-2 causes clinically similar milder forms of disease in most patients, but moderate to severe disease requiring hospitalizations in about 15-20% of infected persons. These similarities imply that hCoV-NL63 should be a reasonable model virus for antiviral cell culture and animal studies in BSL2 environment in the course of antiviral drug development for SARS-CoV-2.About NanoViricidesNanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company does not currently have a license to the coronavirus field, however, TheraCour has not denied any licenses to the Company. The Company typically begins the licensing process only after demonstrating effectiveness of some candidates in optimization stage.This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.As with any drug development efforts, there can be no assurance that any of these candidates would show sufficient effectiveness and safety for human clinical development at this time.There can be no assurance that the Company will be successful in establishing the necessary collaborations, although the Company has been successful at establishing necessary collaborations for its drug programs in the past.FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls". PHEBRA SIGNS INTERNATIONAL DISTRIBUTION AGREEMENT FOR MANUFACTURE AND SUPPLY OF A NEW PHARMACEUTICAL FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY 2020-05-19T06:17:55Z phebra-signs-international-distribution-agreement-for-manufacture-and-supply-of-a-new-pharmaceutical-for-treatment-of-duchenne-muscular-dystrophy Media Release: Sydney. Australia. 18 May, 2020.       PHEBRA SIGNS INTERNATIONAL DISTRIBUTION AGREEMENT FOR MANUFACTURE AND SUPPLY OF A NEW PHARMACEUTICAL FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY   Leading Australian pharmaceutical firm, Phebra Pty Ltd, is pleased to announce it has signed an agreement with Michigan-based Phrixus Pharmaceuticals Inc. (‘Phrixus’) to manufacture and distribute  (Carmeseal-MDÔ) and to assist Phrixus with its clinical trials. This new drug from Phrixus is expected to aid Duchenne muscular dystrophy (DMD) in patients suffering cardiac and respiratory deficits.   DMD is a crippling, degenerative disease, primarily affecting boys and young men, leading to muscular weakness, respiratory distress and early death through heart failure.   The Phrixus compound is a small sterile preparation intended for daily subcutaneous administration. It is a unique speciality treatment for patients with DMD, which aims at modulating cellular damage and assisting with the stabilisation and preservation of the plasma membrane, which results from a loss of functional muscle dystrophin protein.   The effect of reducing muscle damage in key organs leads to an improved survival of these cells, which translates into improved function of the heart, the diaphragm and skeletal limb muscle for patients with DMD.   Announcing the agreement today, Phebra Chief Executive Officer, Dr Mal Eutick said: “Phebra is delighted to have concluded this agreement with Phrixus for the manufacture and distribution of this very important disease modifying, speciality drug.”   “DMD is a progressive and devastating genetic disease and Phebra looks forward to working closely with Phrixus and the Duchenne muscular dystrophy communities to achieve favourable outcomes and improve the lives of those patients concerned.”   “This latest agreement strengthens Phebra’s commitment to pursuing the treatment of rare diseases in Australia and across the world.”   About Phebra:   Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.   At Phebra, we create critical medicines that save and improve lives.     Phebra media contact: Richard Lenarduzzi. +61 411 254 390   Australian based temperature sensor manufacturer assists in times of crisis 2020-05-19T05:00:48Z australian-based-temperature-sensor-manufacturer-assists-in-times-of-crisis Australian owned temperature sensor manufacturer, Pyrosales, is operating at critical capacity during the current COVID-19 pandemic. As Australia’s longest established manufacturers of precision temperature, level and flow measurement gauges, sensors and instrumentation, as well as calibration devices, they are helping out the essential services in need. When it comes to the Australian essential services, Pyrosales has always worked with them, even before the pandemic. Assisting with supply and manufacture for the Medical Industry, the most common products are the infrared thermometer to measure the temperature of individuals in a quick and accurate manner and thermal imaging devices that can detect variations in temperature of individuals. Hospitals and private medical businesses can rely on the team at Pyrosales to supplying refrigeration temperature equipment for medicines, blood and IVF storage as well as maintaining the equipment for sterilization, and of course food temperature control. They are also working to help our aged care facilities to control the temperature of their food and medicine. Pyrosales continue to help out the essential services by ensuring food plant manufacturers have adequate thermocouples, RKC temperature controllers, temperature and pressure gauges to maintain food production. “We have solutions for businesses to monitor their employees for fever temperature. Companies are investigating new ways to measure for the virus to reduce the spread into their workplace. Pyrosales has many products to suit any businesses requirements whether it is to meet the volume of employees, their price range or on-site technology. We not only supply to the medical and industrial market, we are also seeing an increase in demand for people to use in their homes,” said our CEO, John Shanahan. With many businesses in Australia struggling in the current climate, it is positive to see an Australian owned business working not only to help those who need it but are helping boost the economy and keep people in jobs. About Pyrosales Pyrosales is Australia’s longest established and largest manufacturers of precision temperature, level and flow measurement gauges, sensors and instrumentation, as well as calibration devices. The company has developed a reputable position in Australia and internationally as a leading provider of specialist design, manufacture and repair services, especially in applications involving extreme heat conditions. Proudly Australian-owned, Pyrosales has operations in Sydney, Melbourne and Brisbane as well as in South America, China and the United States. The company remains a leading exporter of temperature sensors to Singapore, Philippines, Indonesia, Thailand, Hong Kong, India, China, Belgium, Germany, Malaysia, Zambia, South Africa, Sri Lanka and South America. Pyrosales now has 28 employees, with many having been with the company for 20 years or more. Their knowledge and understanding of the customers’ requirements ensure that a solution for their temperature needs can be provided no matter the difficulty. This service to Australian Industry has both been recognised and rewarded as recipients of business awards and finalist selections: Winner - 2009 Suncorp Business of the YearWinner - 2009 Suncorp Award for Excellence in Developing an Export MarketFinalist - 2009 Australian Institute of Export - Premier's NSW Export Awards Finalist - 2018 Australian Institute of Export - Premier's NSW Export Awards Sentry Medical doing their part for QLD Health in the COVID-19 crisis 2020-05-15T02:34:17Z sentry-medical-doing-their-part-for-qld-health-in-the-covid-19-crisis Sentry Medical and representatives of Queensland Health and Government have been working tirelessly behind the scenes, ensuring the delivery of much needed stock including 8 surgical million masks to aid with pandemic needs. Touchdown of the first flight, earlier this month and the second following this week brings much needed relief for urgent supplies imperative for Queensland Health facilities to remain operational whilst keeping their patients and staff protected. “We’re working around the clock with supply chain partners to ensure we can assist in providing some of the (surgical masks and isolation gowns) demand in Australia”, said Michael O’Brien, National Sales Manager, Sentry Medical. “It’s rewarding to see Sentry can help our front line workers, even in a small way”. Through this surge in global demand for personal protective equipment, Sentry has ensured the delivery of high quality products as well as stable manufacturing, whilst continually exceeding Australian standards on their ranges. “Compromising on our values to deliver inferior products is just not an option,” said Mr O’Brien. “Putting end users at potential risk of less than the stated protective standards is something we will not entertain”. About Sentry Medical For over 25 years, Sentry Medical has served the needs of the Australian and New Zealand health sectors by providing quality medical and surgical consumables, designed to meet the needs of today’s healthcare professionals and patients’ requirements. 100% Australian owned, Sentry Medical is accredited to ISO13485 and maintains control over all of the manufacturing processes to ensure all Sentry branded products comply with stringent quality standards. This also allows Sentry to provide innovative products and solutions that improve quality of life, reduce costs and improve patient care.  A customer focused company, Sentry’s key personnel have extensive knowledge regarding medical consumables and devices, enabling it to provide essential services such as in-house or on-site product education and training. www.sentrymedical.com.au Canberra Foot and Ankle Clinic Takes a Different Approach to Treatment 2020-05-14T06:13:46Z canberra-foot-and-ankle-clinic-takes-a-different-approach-to-treatment The feet support the weight of the body every day and Dr. Kyle Dedini, owner of Canberra Foot and Ankle Clinic, understands the many ways in which the foot can be injured. The practice offers a different approach to treatment for people at every stage of life to keep their feet and ankles healthy. The highly personalized approach to foot and ankle health focuses on the circumstances of the individual, along with the specific reason they’re seeking assistance. Treatment plans factor in the individual’s lifestyles, goals, daily schedules, and budgets. The entire emphasis at the clinic is on the foot and ankle, enabling the practice to develop unique plans for conditioning, rehabilitation, strengthening, and designing orthotics when appropriate. The podiatrist Gungahlin treats individuals of all ages and at every stage of life. The practice can assist parents with information about selecting the best shoes for their child, fungal nail infections, and treating warts. The clinic provides rehabilitation of injuries sustained during accidents or sports participation, biomechanical assessments for coordination difficulties, and assistance to improve performance. Pain from injuries, arthritis, and numbness in the feet and ankles are all treated, along with difficulties arising from diabetes and other chronic conditions. Surgical options are available for ingrown toenails, and discreet orthotics can relieve pain while improving movement and functionality. Strengthening and rehabilitation are employed at the heel pain clinic Canberra to heal injuries, prepare athletes for their endeavors, and aid in mitigating the potential for future injuries. The approach to health and wellness at Canberra Foot and Ankle Clinic is a methodology that has earned the clinic the appellation of “best podiatrist Canberra” by satisfied patients. Healthy feet and ankles are essential for continued mobility, enabling individuals to pursue the lifestyle they desire. About Canberra Foot and Ankle Clinic Canberra Foot and Ankle Clinic treats all aspects of the foot and ankle. Unlike other podiatry clinics that treat the hip, knee and ankle, we – although trained in the whole lower limb – as a clinic have decided to focus solely on the foot and ankle, and partner with other health professionals that focus on the knee upwards. Media Contact Dr. Kyle Dedini Canberra Foot and Ankle Clinic  Phone: 02 6163 4200 Salvation Army Tuggerah Lakes extends a hand to help deliver tech for remote monitoring and reporting of COVID-19 patients 2020-05-11T23:12:00Z salvation-army-tuggerah-lakes-extends-a-hand-to-help-deliver-tech-for-remote-monitoring-and-reporting-of-covid-19-patients Central Coast, AUSTRALIA, May 12, 2020 – Although they couldn’t pick up or deliver the pre-loved items normally generously donated by the Australian public for sale in their thrift stores, “the Salvos” as they are more affectionately known, lent their hand to Caretaker Medical, the global leader in Remote Wireless Patient Monitoring to ensure safe delivery of 250 devices to NSW Health Pathology in Newcastle.   With COVID-19 effecting business all across the world, the Salvos made the decision to close all Salvos Stores, Family Stores and thrift shops to the public while the COVID‑19 pandemic continues to threaten the health and safety of Australians.   As we know, nothing stops the Salvos from lending a help in hand in a time of need and they did exactly that when Caretaker Medical needed them the most. Led by Pastor Bill Geracia, The Salvation Army Tuggerah Lakes kindly donated the use of their truck and salvo’s member, Dean Holloway kindly donated his time to get this critical equipment from Gosford to Newcastle.   “Supporting the community is in our DNA and we are there to help regardless of the location, circumstances or situation”, said Pastor Bill Geracia. “It’s extremely rewarding to be able to help others and certainly in the time of a crisis like COVID-19 that has effected so many, in so many countries around the world,” said Bill.   Caretaker Medical is the company behind Australia's first 'virtual hospital’ and will be used to monitor COVID-19 patients in their homes, to help reduce the potential spread of the disease to healthcare workers and to reduce the capacity requirement on the Australian healthcare system.   “The Caretaker devices will be used to monitor patients in their homes who have moderate symptoms of the virus, and will continuously track their vital signs, including heart rate, temperature, oxygen saturation, beat-by-beat blood pressure and breathing”, said Mark Winter, Chief Executive Officer at inTechnology Distribution, Caretakers local distributor.   “A team of doctors, supported by artificial intelligence technology provided by The University of New England in partnership with New South Wales Health, will continuously monitor their status, and if their conditions worsen, we will bring them into the hospital for emergency care”, he concluded.   More Virtual hospitals are expected to be rolled out across Australia, as Australia's healthcare system braces for an enormous surge of coronavirus patients, potentially overwhelming hospital capacity. It is clear that there is an urgent need to find safe ways to keep non critically ill patients out of hospital and in the comfort of their own home.   About Caretaker Medical Caretaker Medical® based in Charlottesville, Virginia, was founded in March 2014 to commercialize wireless patient monitoring devices built around its Patented Pulse Decomposition Analysis technology.   The company has developed the Caretaker wearable wireless vital signs monitoring system that sets a new standard in portability, simplicity, and medical-grade patient monitoring.  Using a small, comfortable finger cuff, Caretaker accurately measures continuous non-invasive beat-by-beat Blood Pressure (“CNIBP”), ECG-Accurate Heart Rate, and Respiration Rate, as well as Blood Volume (for hemorrhage detection), Arterial Stiffness, and other hemodynamic parameters.   Clinical trials have validated that Caretaker measurements are equivalent to other CNIBP patient monitors and heart rate methods. The company anticipates that its innovative approach to vital sign monitoring will be widely accepted in the medical community while disrupting existing patient monitoring solutions.   For more information about Caretaker Medical, and the Caretaker4 wireless Beat-by-Beat remote patient monitor please visit: http://www.caretakermedical.com.au/   About The Salvation Army The Salvation Army Australia is an international Christian movement, united by faith and giving hope where it’s needed most. Across Australia – in cities, country towns and rural communities – our work touches every demographic and age group.  We’re involved in national issues while also bringing hope to people who may be experiencing hardship or injustice.   Since our foundations in nineteenth century London, we express our faith in charitable work to provide both the spiritual and the social support.  We believe that with one hand we reach out to God and with the other we reach out to the world.   As both a church and charity, we can preach and speak about justice, compassion, and other issues that support the welfare of others and see them as a whole person – body, mind and spirit.   Interactive online breastfeeding education for expectant parents 2020-05-10T22:42:28Z interactive-online-breastfeeding-education-for-expectant-parents The Australian Breastfeeding Association (ABA) has introduced new online breastfeeding education sessions to give support and information to families. Breastfeeding Education Live (BEL) interactive webinars are led by qualified breastfeeding educators. They cover topics like how to position and attach a baby to the breast, read a baby’s cues and whether the baby is getting enough milk. There is also information on resources and support they can use when the baby arrives. BEL webinars were designed to allow all families access to breastfeeding information even if they live in remote or rural areas. They are even more welcome, now that many other services are closed due to COVID-19. BELs are held on weekends and some weeknights. Registration is through the ABA website. Sessions cost $20 for ABA Members and $125 for non-members. ‘A lot of expectant parents have never held a baby, let alone seen one being breastfed’, says Margaret Grove, ABA President. ‘Many have missed out on the traditional learning through the generations. That’s why it’s so important that they have access to the kind of prenatal education that ABA is providing.’ ‘Online sessions are different from face-to-face interaction but they have many benefits. Many enjoy attending BELs from the comfort of their own home. They are able to ask questions and interact with other expectant parents in a small group.’ ‘The aim is to empower expectant parents and give them the confidence they need to breastfeed their baby.’ ENDS Spokesperson Margaret Grove 0414 773 714 To arrange an interview with another Australian Breastfeeding Association spokesperson, please contact marketing@breastfeeding.asn.au Nitty Brown 0412 675 092 Lizzie Stafford 0402 542 852 Photo Opportunity Photos available on request. Contact marketing@breastfeeding.asn.au Resources For more information about Breastfeeding Education Live visit https://www.breastfeeding.asn.au/classes Find out about ABA services available during the COVID-19 pandemic: https://www.breastfeeding.asn.au/bf-info/aba-services-downloadable-flyer For more information about breastfeeding and COVID-19 visit: https://www.breastfeeding.asn.au/bfinfo/covid-19 About the Australian Breastfeeding Association: The Australian Breastfeeding Association (ABA) is Australia's largest breastfeeding information and support service, providing assistance to more than 80,000 mothers each year. ABA also provides up-to-date information and continuing education for thousands of health professionals working with mothers and babies. It is our vision that breastfeeding is recognised as important by all Australians and is culturally normal. As Australia’s leading authority on breastfeeding, we support, educate and advocate for a breastfeeding inclusive society. https://www.breastfeeding.asn.au/ Growing Concern for Patients as Lockdown Continues 2020-05-06T21:59:47Z growing-concern-for-patients-as-lockdown-continues An extension of Level 3 would be devastating for the health and wellbeing of New Zealanders, says the NZCA.  Thousands of patients are crying out for care, and chiropractors are feeling the strain of having to continually turn people away.    Any extension of the restrictions to the delivery of hands-on healthcare will leave thousands of New Zealanders with decreased health, increased dysfunction and worsening mental, physical and emotional stress, notes the NZCA. Chiropractors and other allied health professions in Australia have continued to practice without compromising community safety, and the profession is feeling increasingly frustrated in New Zealand.   NZCA President and chiropractor Dr Hayden Thomas says: `The health and wellness of New Zealanders is our primary concern and the denial of access to healthcare must be addressed urgently. Our colleagues in Australia have been permitted to continue in practice with appropriate procedural controls, and with advanced contact tracing monitoring there have been no reports of community spread from this. We are asking for everyone to adhere to the Level 3 regulations so that we can get back to assisting our patients and our members can return to usual practice as soon as possible’.   Auckland chiropractor Dr Simon Kelly points out that: `More than 56,000 kiwis a week would normally seek an appointment with a chiropractor. Every day that we stay in lockdown, the backlog of patients grows and the knock-on effect to New Zealand business worsens as they are unable to work.  People are suffering and we know that their state of health is declining. Not only that, many of them are being forced to use medications and cope with the associated side effects they can have. Telehealth is not a solution for many of our patients as chiropractic is a hands-on healthcare discipline. We are highly-trained, responsible healthcare practitioners and should be able to exercise our clinical judgement as to when it is appropriate to see a patient during the pandemic.’   Dr Thomas says: `Our members are reporting hundreds of requests for care, such as builders who can’t go to work, dairy farmers incapacitated and unable to milk their herds and SME owners who cannot run their businesses because they cannot get the care they need.  Also affected are nurses, police, paramedics, fire and emergency staff and others who understandably need to be functional to deliver their essential services.  These people and many others rely on the care that chiropractors provide. This need is growing every day and chiropractors are getting increasing pressure from their communities for care. If we are able to keep essential care providers at work and provide care to other patients, it will assist in keeping other parts of the health service free for other urgent work and COVID-19 assessment and treatment.’   While chiropractors are able to communicate via Telehealth with patients to offer advice, self-care and exercises from isolation, all face-to-face consultations are severely restricted under level 3.  Many chiropractors are offering Telehealth appointments free of charge as an added service to their patients.   Chiropractors are primary health care professionals registered under the HPCA Act with close to 700 Annual Practicing Certificate holders working in solo, group, and multidisciplinary practices around New Zealand. New Zealand chiropractors have significant training (a minimum 5-year tertiary degree) and a broad yet highly skilled ​scope of practice and clinical expertise in neuro-musculo-skeletal health including manual spinal and extremity care, radiography and radiology, orthopaedics, neurology, rheumatology, physiology and pathology.    NZCA chiropractors are taking the lead to inform and inspire people to improve health, promote wellness, and prevent dysfunction by educating the public to have a greater understanding of the relationship between their spine and nervous system by improving their posture, addressing and preventing spinal problems, and engaging in physical activity.   ­Ends       New Queensland Research Centre Aims to Fast-track COVID-19 Research 2020-05-06T04:51:37Z new-queensland-research-centre-aims-to-fast-track-covid-19-research New Queensland Research Centre Aims to Fast-track COVID-19 Researchto Inform Patient Treatment Now   Brisbane, QLD (WMR) May 6th 2020 – The new Wesley Medical Research COVID-19 Rapid Response Research Centre seeks to fast-track answers in the fight against COVID-19 through cutting edge research. While the global health crisis continues to take a major toll on lives and livelihoods, questions to prevent, diagnose and treat COVID-19 remain unanswered. The launch of a new virtual research centre by Wesley Medical Research advances local and international research through patient-centred collaboration. The Wesley Medical Research COVID-19 Rapid Response Research Centre comprises a dedicated team of world-leading researchers and healthcare professionals who are committed to conducting research that delivers immediate improvements to the prevention, diagnosis, treatment and management of COVID-19. “Despite the devastation that COVID-19 has brought to our world, I am humbled by the way in which the global community has come together to combat this deadly virus,” said Dr Claudia Giurgiuman, Wesley Medical Research General Manager. “And I am thrilled that our organisation can truly be a part of the solution.” “The Rapid Response Research Centre will allow us to rapidly respond to evolving knowledge and information and answer the research questions that matter the most to patients right now.” By establishing strong collaborations with hospitals and research institutions in Australia and around the world, the Centre will contribute to the global understanding of COVID-19 and arm experts with the answers that they need to battle the virus. The COVID-19 Rapid Response Research Centre urgently needs funding to advance this program of research.  The Wesley Medical Research COVID-19 Emergency Appeal was launched in mid-April to raise $1.4 million to fast track its critical program of work and invest in emerging COVID-19 research initiatives. For more information: COVID-19 Rapid Response Research Centre (includes details of priority research projects) https://www.wesleyresearch.org.au/what-we-do/covid-19-rapid-response-research-centre/ COVID-19 Emergency Appealhttps://www.wesleyresearch.org.au/covid-19-emergency-appeal/ ABOUT WESLEY MEDICAL RESEARCH: Wesley Medical Research is an independent, not-for-profit organisation based in Brisbane, Queensland. We conduct medical research with a strong focus on improving patient care and quality of life. Our clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of illness and disease. We collaborate with doctors, nurses, and allied health professionals to accelerate contemporary care.   Mun delivers 200,000 face masks in latest PPE shipment to NSW Health 2020-05-06T01:06:08Z mun-delivers-200-000-face-masks-in-latest-ppe-shipment-to-nsw-health SYDNEY, AUSTRALIA – 6th May 2020 – Mun (Australia) Pty Ltd completed its latest delivery of vital personal protective equipment (PPE) for healthcare workers on the frontline in NSW, including a shipping container with almost 200,000 face masks. The shipment, which is bound for public hospitals in NSW, is the most recent effort by Mun Australia to ensure healthcare workers are well protected during the COVID-19 pandemic. Over the course of this unprecedented time Mun has been supplied NSW Health with tens of millions of gloves, hundreds of thousands of masks, aprons and caps, and tens of thousands of gowns.  “We are so grateful of the work our frontline healthcare workers have been doing for our communities during this unprecedented global pandemic. There has been enormous demand for PPE worldwide and I am very appreciative of the hard work our team has put in to secure supplies for our hospital system.” said Leonard Brown, General Manager of Mun Australia. “I am confident in Mun’s capabilities, responsiveness and effectiveness in continuing to support organisations like NSW Health during this difficult time”.   For more than 17 years Mun Australia has established a close working relationship with NSW Health, and provided infection control support across all of the states’ Local Health Districts. Mun’s product range is crucial in protecting the lives of healthcare providers, emergency responders and other essential workers. Mun continues to work hard in providing personal protective equipment that is known for its quality, consistency and reliability during this pandemic.     About Mun Global With offices located in Australia, Malaysia, China and India, Mun is dedicated to produce the best quality gloves across the globe and become the leader for premium healthcare products that enhance peoples’ care, wellbeing and welfare around the world. Every GloveOn® and PrimeOn™ product is created with superior precision, reliability, integrity and quality. Our gloves, PPE and hand care ranges exceed numerous international standards, including AS/NZS, ASTM, EN and ISO, and are TGA compliant. For more information on Mun, visit the company’s website at https://munglobal.com.au   Miracle cream cures Psoriasis in 7 days 2020-05-05T07:48:03Z miracle-cream-cures-psoriasis-in-7-days An Australian lady has been cured of her Psoriasis in just 7 days after months of trying different chemical-based treatments that did not work and if anything made her skin worse!  Sally suffered for the last 6 months and was desperate to find a solution. One month after using antibiotics A family member saw our post on the Face Book page Australian Made Products, where over 1,600,000 Australians share their favourite Australian Made and Owned products, Sally, being skeptical but hopeful, then decided to purchased the Grahams Natural Psoriasis Cream and within 1 week her Psoriasis was cured and no sign of the condition that had haunted her for months was has now disappeared. One day after using Grahams Natural Psoriasis Cream www.grahamsnatural.com.au Psoriasis is a chronic skin disease which can be very debilitating for the 2 million plus Australian sufferers. This is a very heart-warming story that Sally wanted to share with us and the rest of Australia since she received such amazing results so quickly. Accent Home Care & Social Support Group Updates Their COVID-19 Response 2020-05-04T23:51:26Z accent-home-care-amp-social-support-group-updates-their-covid-19-response Accent Home Care, a renowned elderly home care services group, has reported the company’s efforts in dealing with the COVID-19 virus. As many individuals may have concerns during this time of uncertainty, Accent Home Care reassures family members that they remain committed to servicing their clients and are placing their safety as their highest priority at this time.     In line with this, the company has announced that they are in strict compliance with the government-mandated measures to ensure the safety of Accent Home Care members, and are extending precautionary measures so they can deliver the same high-quality care and services as always.     Accent Home Care maintains essential services for home care clients. This means their Case Management team will remain in close contact with clients, ensuring essential services are in place and continuing the provision of essential items such as toilet rolls, hand sanitisers, and masks. Accent Home Care’s “Care Packs” which include toilet rolls, tissue papers, soap, hand sanitisers, and face masks are available for order and will be delivered straight to the client’s door.     The company also extends a shopping assistance service that allows Accent Home Care employees to assist in grocery shopping and medication pick up. According to the company, providing emotional and social support during this difficult time is a crucial part of their care initiative. Therefore, they are offering regular phone calls to check on clients’ emotional and mental conditions, providing social interaction in a newly-contactless world.     Apart from keeping clients safe, the company is taking measures to ensure the safety of their staff and the whole Accent Home Care community. The company does this by requiring all staff, carers, contractors, and volunteers to self-isolate for 14 days if they have travelled anywhere overseas. Additional training has also been put into place to ensure all carers deliver the highest standard of possible care in accordance with preventative health measures to reduce the spread of the virus.     Accent Home Care has also established an infection control committee that includes specialist clinicians, residents, senior managers, and a TTHA Board Representative. This is to ensure company preparedness and responsiveness to any client or staff with COVID-19. The Accent Home Care team will contact the Health Department’s Rapid Response Team if there is any client that has been confirmed to have the novel coronavirus.     The Rapid Response Team will provide additional support at home, including the provision of personal protection equipment (PPE). Accent Home Care will continue to provide care until the Rapid Response Team takes over.    To learn more, visit the Accent Home Care website at https://accenthomecare.org.au/.  AlayaCare’s new Family Portal delivers peace of mind to home care clients and their families amidst pandemic 2020-05-01T13:06:11Z alayacare-s-new-family-portal-delivers-peace-of-mind-to-home-care-clients-and-their-families-amidst-pandemic May 1, 2020 – AlayaCare today announced its revamped Family Portal: a secure, online tool for clients, providers and authorised family members to not only access their health care information from any device, anywhere, but be active participants in their own care plans, too.   The portal is the latest addition to AlayaCare’s Virtual Care Suite, an industry-leading home and community care solution that blends traditional and virtual care to clients anytime, anywhere. Through the HIPAA-compliant portal, clients and their families can manage information about their care plans, schedules, medications, vitals and more. Additionally, clients can complete self-assessments and clinical forms within the portal, and if they choose, share their medical information with family members – all while remaining safe at home.   “There was an unmet need for innovations like our Family Portal, and that need that becomes far more acute now as COVID-19 puts the health of older adults and vulnerable patients at greater risk,” said Adrian Schauer, CEO of AlayaCare. “Using technology to augment human interactions is essential to the delivery of safe, high-quality home care. This will help combat isolation and transform clients from recipients of home care to participants in that care.”   The Family Portal becomes another component of AlayaCare’s approach to the pandemic – developing rapid virtual care solutions that notably includes a COVID-19 electronic screening tool, which enables care providers to assess a client’s risk for infection, and a secure video conferencing feature that seamlessly converts any in-person visit to a virtual one.   Connecting clients, families and care providers   “Consistent and quality communication with our families is crucial. Our families need to know who is working with their child, and how their child is doing,” said Charles Wong, Founder & President, CarePros. “Having the Family Portal allows our families to have easy access to the information they need in order to feel comfortable and have confidence in the care their family is receiving.”   Offering newfound measures of transparency to any home care organisation, AlayaCare’s new premium Family Portal generates real-time updates on schedules, care plans and payments. This brings new levels of efficiency to back-office staff, who no longer need to phone individual clients if there are changes to care plans or schedules. The portal is updated in real-time, accessible anywhere, so that communication is uninterrupted, and new information is clearly documented so all involved in a client’s care have clarity and share the same expectations.    Home and community care organisations interested in learning more about Family Portal can contact AlayaCare any time, whether or not they are currently a client. For more information, visit: https://www.alayacare.com/family-portal   About AlayaCare AlayaCare's unique platform offers a complete technology solution to manage the entire client lifecycle including referrals and intake, scheduling, coordination, client health records, clinical documentation, care worker management, billing and payroll, reporting, remote patient monitoring, and a mobile caregiver app in one integrated, highly robust and secure, cloud-based system. AlayaCare is providing the platform for home and community care organisations to propel towards innovation and home care of the future. AlayaCare was founded in 2014. www.alayacare.com   About CarePros CarePros is an Edmonton based pediatric home care agency, driven to provide the highest level of care for children. CarePros first started providing care in 2016 and since then, its range of services have grown substantially as they continue striving to reach and help more families. https://carepros.ca/